MesGen Biotech

MesGen Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies using a proprietary non-viral gene insertion platform. The company's technology aims to overcome the limitations of traditional viral vectors, such as high manufacturing costs and safety concerns, by providing a more efficient and scalable approach to engineering immune cells. MesGen's lead programs include CAR-T therapies targeting CD19 for hematological cancers and GPC3 for solid tumors like hepatocellular carcinoma. Headquartered in Shanghai, the company is backed by prominent venture capital firms and is advancing multiple candidates through early-stage clinical trials. Their approach emphasizes the use of transposon-based systems to enhance the persistence and efficacy of engineered T cells.